Cover Image
市場調查報告書

體外診斷 (IVD) 的美國市場預測 2020年:免疫檢測、臨床化學、分子診斷學 (MDX) 、微生物學

U.S. In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User & by Region - Forecast to 2020

出版商 MarketsandMarkets 商品編碼 354805
出版日期 內容資訊 英文 179 Pages
訂單完成後即時交付
價格
Back to Top
體外診斷 (IVD) 的美國市場預測 2020年:免疫檢測、臨床化學、分子診斷學 (MDX) 、微生物學 U.S. In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User & by Region - Forecast to 2020
出版日期: 2016年03月17日 內容資訊: 英文 179 Pages
簡介

美國的體外診斷 (IVD) 市場,預計從2015到2020年以4.7%的年複合成長率發展,到2020年達到259億9,000萬美元。慢性疾病、感染疾病的發病率的增加,迅速的人口高齡化,偏好照護現場 (POC) 檢驗、個體化醫療的趨勢高漲,患者保護和醫療費負擔合理化法 (ACA:Affordable Care Act) 的實施,自動化設備的需求增加,及實驗室的自動化成為,促進美國的IVD市場的主要原因。

本報告提供美國的體外診斷 (IVD) 市場相關分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 美國的體外診斷市場上成長可能性
  • 美國的體外診斷市場:各終端用戶
  • 美國的體外診斷市場:地區混合

第5章 市場概要

  • 簡介
  • 市場區隔
    • 各產品
    • 各技術
    • 各應用領域
    • 各終端用戶
  • 市場動態
    • 推動因素
    • 阻礙因素
    • 機會
    • 課題

第6章 美國的體外診斷市場:各產品與服務

  • 簡介
  • 試劑
  • 設備
    • 全自動化設備
    • 半自動化設備
  • 資料管理軟體
  • 服務

第7章 美國的體外診斷市場:各技術

  • 簡介
  • 臨床化學
  • 免疫化學/免疫檢測
  • 微生物學
  • 分子診斷學 (MDX)
  • 血液學
  • 凝固/止血
  • 其他IVD技術

第8章 美國的體外診斷市場:各應用領域

  • 簡介
  • 感染疾病
  • 糖尿病
  • 腫瘤/癌症
  • 心血管疾病
  • 內分泌疾病
  • 免疫疾病
  • 骨、礦物質相關的疾病
  • 肺部疾病
  • 其他應用

第9章 美國的體外診斷市場:各終端用戶

  • 簡介
  • 醫院實驗室
  • 臨床/獨立實驗室
  • 其他終端用戶

第10章 競爭環境

  • 簡介
  • 市場佔有率分析
  • 競爭情形、趨勢

第11章 企業簡介 (概要、財務、產品&服務、策略、發展趨勢)

  • ABBOTT LABORATORIES, INC.
  • DANAHER CORPORATION
  • JOHNSON AND JOHNSON
  • ROCHE DIAGNOSTICS
  • SIEMENS HEALTHCARE
  • BECTON, DICKINSON AND COMPANY
  • BIOMERIEUX
  • BIO-RAD LABORATORIES, INC.
  • SYSMEX CORPORATION
  • THERMO FISHER SCIENTIFIC, INC.
  • QIAGEN N.V.

第12章 附錄

圖表

目錄
Product Code: MD 4174

In vitro diagnostics testing is an indispensable tool in the modern medical practice. IVD tests are conducted with the help of various medical devices for the diagnosis of a number of diseases. With evolution in biotechnology, there has been a drastic change in the type of tests conducted for diagnosing various diseases, thus helping physicians to diagnose and treat diseases promptly and effectively. The most important trend witnessed recently in the U.S. IVD industry is the trend of self-testing as opposed to patients visiting hospitals. This is a key factor driving the growth of point-of-care testing, as patients prefer self-testing to avoid hospital visits. IVD tests have a significant role in the prevention, monitoring, diagnosis, and treatment of diseases. Common IVD tests include blood tests for glucose, tests for detection of electrolytes (calcium, sodium, and potassium), liver enzymes, and drug tests.

The U.S. IVD market is projected to reach USD 25.99 billion by 2020 at a CAGR of 4.7% from 2015 to 2020. The rising incidence of chronic and infectious diseases, rapidly aging population, growing preference for point-of-care testing and personalized medicine, implementation of the Affordable Care Act (ACA), increasing demand for automated instruments, and automation in laboratories are key factors driving the IVD market in the U.S. In this report, the market is segmented by product & service, technology, application, end user, and region.

The U.S. IVD product & services market is broadly segmented into reagents, instruments, services, and data management system/software. The instruments market is further segmented into fully automated instruments, semi-automated instruments, and other instruments. The fully automated instruments segment accounted for the largest share of the U.S IVD instruments market in 2014. The increasing number and complexity of tests, coupled with a shortage in laboratory staff, is driving the greater adoption of fully automated instruments in laboratories.

On the basis of end user, the U.S. IVD market is segmented into hospital laboratories, clinical/independent laboratories, and others. In 2014, the hospital laboratories segment accounted for the largest share of the U.S. IVD market in the U.S. The high inpatient flow and ancillary outpatient flow in hospitals, growing prevalence of chronic and infectious diseases, and increasing number of accredited laboratories are key factors driving market growth in this end-user segment.

The major players in the U.S. IVD market are Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickson and Company (U.S.), Johnson & Johnson (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Siemens Healthcare (Germany), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Alere Inc. (U.S.), Ortho-Clinical Diagnostics Inc. (U.S.), and bioMerieux (France).

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for reaping greater market shares.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by top players in the U.S. IVD market. The report analyzes the U.S. IVD market by product, technology, end user, and application across all regions
  • Product Development/Innovation: Detailed insights on upcoming trends, R&D activities, and new product launches in the U.S. IVD market
  • Market Development: Comprehensive information on the lucrative emerging markets by product, technology, end user, application, and region
  • Market Diversification: Exhaustive information about new products, growing regions, recent developments, and investments in the U.S. IVD market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and SWOT analyses of leading players in the U.S. IVD market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. GROWTH POTENTIAL OF THE U.S. IN VITRO DIAGNOSTICS MARKET
  • 4.2. U.S. IN VITRO DIAGNOSTICS MARKET, BY END USER (2014)
  • 4.3. U.S. IN VITRO DIAGNOSTICS MARKET, REGIONAL MIX

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY PRODUCT
    • 5.2.2. BY TECHNOLOGY
    • 5.2.3. BY APPLICATION
    • 5.2.4. BY END USER
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Rapid growth in geriatric population and increasing incidence of chronic diseases in the U.S.
      • 5.3.1.2. Increasing adoption of point-of-care (POC) testing
      • 5.3.1.3. Growing awareness on personalized medicine
      • 5.3.1.4. Rise in reagent rental agreements
      • 5.3.1.5. Implementation of the Affordable care Act (ACA)
      • 5.3.1.6. Increasing adoption of automated instruments and automation in laboratories
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Unfavorable reimbursement scenario
      • 5.3.2.2. Rising healthcare costs and low budgets
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Condition-specific markers and tests with advances in genomics and proteomics
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Stringent regulatory framework

6. U.S. IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1. INTRODUCTION
  • 6.2. REAGENTS
  • 6.3. INSTRUMENTS
    • 6.3.1. FULLY AUTOMATED INSTRUMENTS
    • 6.3.2. SEMI-AUTOMATED INSTRUMENTS
    • 6.3.3. OTHERS
  • 6.4. DATA MANAGEMENT SOFTWARE
  • 6.5. SERVICES

7. U.S. IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. CLINICAL CHEMISTRY
  • 7.3. IMMUNOCHEMISTRY/IMMUNOASSAYS
  • 7.4. MICROBIOLOGY
  • 7.5. MOLECULAR DIAGNOSTICS (MDX)
  • 7.6. HEMATOLOGY
  • 7.7. COAGULATION/HEMOSTASIS
  • 7.8. OTHER IVD TECHNOLOGIES

8. U.S. IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. INFECTIOUS DISEASES
  • 8.3. DIABETES
  • 8.4. ONCOLOGY/CANCER
  • 8.5. CARDIOVASCULAR DISORDERS
  • 8.6. ENDOCRINE DISORDERS
  • 8.7. AUTOIMMUNE DISEASES
  • 8.8. BONE & MINERAL-RELATED DISEASES
  • 8.9. PULMONARY DISEASES
  • 8.10. OTHER APPLICATIONS

9. U.S. IN VITRO DIAGNOSTICS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITAL LABORATORIES
  • 9.3. CLINICAL/INDEPENDENT LABORATORIES
    • 9.3.1. LARGE LABORATORIES/REFERENCE LABORATORIES
    • 9.3.2. MEDIUM-SIZED LABORATORIES
    • 9.3.3. SMALL LABORATORIES
  • 9.4. OTHER END USERS

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. NEW PRODUCT LAUNCHES
    • 10.3.2. COLLABORATIONS, AGREEMENTS, & PARTNERSHIPS
    • 10.3.3. APPROVALS
    • 10.3.4. MERGERS & ACQUISITIONS
    • 10.3.5. OTHERS

11. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 11.1. ABBOTT LABORATORIES, INC.
  • 11.2. DANAHER CORPORATION
  • 11.3. JOHNSON AND JOHNSON
  • 11.4. ROCHE DIAGNOSTICS
  • 11.5. SIEMENS HEALTHCARE
  • 11.6. BECTON, DICKINSON AND COMPANY
  • 11.7. BIOMERIEUX
  • 11.8. BIO-RAD LABORATORIES, INC.
  • 11.9. SYSMEX CORPORATION
  • 11.10. THERMO FISHER SCIENTIFIC, INC.
  • 11.11. QIAGEN N.V.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. OTHER DEVELOPMENTS
  • 12.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.6. AVAILABLE CUSTOMIZATIONS
  • 12.7. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASED INCIDENCE OF CHRONIC DISEASES AND RAPID GROWTH IN GERIATRIC POPULATION WILL DRIVE THE MARKET GROWTH
  • TABLE 2: UNFAVORABLE REIMBURSEMENT AND RISING HEALTHCARE COSTS TO RESTRAIN MARKET GROWTH
  • TABLE 3: CONDITION SPECIFIC MARKERS, AN AREA OF OPPORTUNITY
  • TABLE 4: STRINGENT & UNCERTAIN REGULATIONS, A KEY CHALLENGE FOR THE IVD MARKET
  • TABLE 5: U.S. IVD MARKET SIZE, BY PRODUCT & SERVICE, 2013-2020 (USD MILLION)
  • TABLE 6: U.S.: IVD MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 7: U.S. IVD REAGENTS MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 8: U.S. IVD INSTRUMENTS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 9: U.S. IVD INSTRUMENTS MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 10: U.S. IVD DATA MANAGEMENT SOFTWARE MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 11: U.S. IVD SERVICES MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 12: U.S. IVD MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION)
  • TABLE 13: U.S. CLINICAL CHEMISTRY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 14: U.S. IMMUNOCHEMISTRY/IMMUNOASSYS MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 15: U.S. MICROBIOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 16: U.S. MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 17: U.S. HEMATOLOGY MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 18: U.S. COAGULATION/HEMOSTASIS MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 19: U.S. OTHER IVD TECHNOLOGIES MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 20: U.S. IVD MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 21: INFECTIOUS DISEASE INCIDENCE IN THE U.S., 2008-2012
  • TABLE 22: HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVALENCE IN THE U.S., BY REGION
  • TABLE 23: U.S. IVD MARKET SIZE, FOR INFECTIOUS DISEASES BY END USER, 2013-2020 (USD MILLION)
  • TABLE 24: DIABETES INCIDENCE IN THE U.S., BY REGION, 2008-2012
  • TABLE 25: U.S. IVD MARKET SIZE, FOR DIABETES BY END USER, 2013-2020 (USD MILLION)
  • TABLE 26: CANCER INCIDENCE RATE IN THE U.S., BY REGION (PER 100,000 INDIVIDUALS), 2008-2012
  • TABLE 27: U.S. IVD MARKET SIZE, FOR ONCOLOGY/CANCER BY END USER, 2013-2020 (USD MILLION)
  • TABLE 28: U.S. IVD MARKET SIZE, FOR CARDIOVASCULAR DISORDERS BY END USER, 2013-2020 (USD MILLION)
  • TABLE 29: OBESITY INCIDENCE RATE IN THE U.S., BY REGION (PER 100,000 INDIVIDUALS), 2008-2012
  • TABLE 30: U.S. IVD MARKET SIZE, FOR ENDOCRINE DISORDERS BY END USER, 2013-2020 (USD MILLION)
  • TABLE 31: ARTHRITIS INCIDENCE IN THE U.S., BY REGION, 2011 & 2013
  • TABLE 32: U.S. IVD MARKET SIZE, FOR AUTOIMMUNE DISEASES BY END USER, 2013-2020 (USD MILLION)
  • TABLE 33: U.S. IVD MARKET SIZE, FOR BONE & MINERAL-RELATED DISEASES BY END USER, 2013-2020 (USD MILLION)
  • TABLE 34: ASTHMA PREVALENCE IN THE U.S., BY AGE, 2007-2011
  • TABLE 35: U.S. IVD MARKET SIZE, FOR PULMONARY DISEASES BY END USER, 2013-2020 (USD MILLION)
  • TABLE 36: U.S. IVD MARKET SIZE, FOR OTHER APPLICATIONS BY END USER, 2013-2020 (USD MILLION)
  • TABLE 37: U.S.: IVD MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 38: U.S.: IVD MARKET SIZE FOR HOSPITAL LABORATORIES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 39: U.S.: IVD MARKET SIZE FOR HOSPITAL LABORATORIES, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 40: U.S.: IVD MARKET SIZE FOR CLINICAL LABORATORIES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 41: U.S.: IVD MARKET SIZE FOR CLINICAL LABORATORIES, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 42: U.S.: IVD MARKET SIZE FOR CLINICAL LABORATORIES, BY LABORATORY SIZE, 2013-2020 (USD MILLION)
  • TABLE 43: U.S.: IVD MARKET SIZE FOR OTHER END USER, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 44: U.S.: IVD MARKET SIZE FOR OTHER END USERS, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 45: GROWTH STRATEGY MATRIX, 2012-2015
  • TABLE 46: NEW PRODUCT LAUNCHES, 2014-2015
  • TABLE 47: COLLABORATIONS, AGREEMENTS, & PARTNERSHIPS, 2014-2016
  • TABLE 48: APPROVALS, 2015
  • TABLE 49: MERGERS & ACQUISITIONS, 2014-2016
  • TABLE 50: OTHERS, 2014-2015

LIST OF FIGURES

  • FIGURE 1: U.S. IN VITRO DIAGNOSTICS MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: U.S. IVD MARKET SIZE, BY PRODUCTS & SERVICES, 2015 VS. 2020 (USD MILLION)
  • FIGURE 7: U.S. IVD INSTRUMENTS MARKET SIZE, BY TYPE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 8: U.S. IVD MARKET SIZE, BY TECHNOLOGY, 2015 VS. 2020 (USD MILLION)
  • FIGURE 9: U.S. IVD MARKET SIZE, BY APPLICATION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 10: U.S. IVD MARKET SIZE, BY END USER, 2015 VS. 2020 (USD MILLION)
  • FIGURE 11: U.S. IVD MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION)
  • FIGURE 12: GROWING PREVALENCE OF CHRONIC DISEASES AND INCREASING DEMAND FOR AUTOMATED INSTRUMENTS TO DRIVE MARKET GROWTH
  • FIGURE 13: HOSPITAL LABORATORIES ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. IVD END-USERS MARKET IN 2014
  • FIGURE 14: SOUTH REGION TO DOMINATE THE U.S. IVD MARKET DURING 2015 TO 2020
  • FIGURE 15: U.S. IN VITRO DIAGNOSTICS MARKET SEGMENTATION, BY PRODUCT
  • FIGURE 16: U.S. IN VITRO DIAGNOSTICS MARKET SEGMENTATION, BY TECHNOLOGY
  • FIGURE 17: U.S. IN VITRO DIAGNOSTICS MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 18: U.S. IN VITRO DIAGNOSTICS MARKET SEGMENTATION, BY END USER
  • FIGURE 19: U.S. IVD MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 20: NUMBER OF PATIENTS WITH CHRONIC CONDITION IN THE U.S. (IN MILLION)
  • FIGURE 21: REAGENTS, THE FASTEST GROWING SEGMENT OF THE U.S. IVD MARKET DURING 2015-2020
  • FIGURE 22: THE MOLECULAR DIAGNOSTICS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 23: ONCOLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 24: PREVALENCE OF CARDIOVASCULAR DISEASES IN ADULTS AGED ≥20 YEARS
  • FIGURE 25: U.S. IVD MARKET SIZE, BY END USER, 2015 VS. 2020 (USD MILLION)
  • FIGURE 26: U.S. CLINICAL LABORATORIES MARKET SIZE, BY TYPE, 2015 VS. 2020 (USD MILLION)
  • FIGURE 27: MARKET PLAYERS ACTIVELY ADOPTED NEW PRODUCT LAUNCHES AS A KEY GROWTH STRATEGY BETWEEN 2012 AND 2015
  • FIGURE 28: U.S. IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, 2014
  • FIGURE 29: BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY
  • FIGURE 30: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS
  • FIGURE 31: COMPANY SNAPSHOT: ABBOTT LABORATORIES, INC.
  • FIGURE 32: COMPANY SNAPSHOT: DANAHER CORPORATION
  • FIGURE 33: COMPANY SNAPSHOT: JOHNSON AND JOHNSON
  • FIGURE 34: COMPANY SNAPSHOT: F. HOFFMANN-LA ROCHE LTD.
  • FIGURE 35: COMPANY SNAPSHOT: SIEMENS AG 112  
  • FIGURE 36: COMPANY SNAPSHOT: BECTON, DICKINSON AND COMPANY
  • FIGURE 37: COMPANY SNAPSHOT: BIOMERIEUX
  • FIGURE 38: COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC.
  • FIGURE 39: COMPANY SNAPSHOT: SYSMEX CORPORATION
  • FIGURE 40: COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC.
  • FIGURE 41: COMPANY SNAPSHOT: QIAGEN N.V.
Back to Top